Association of Retinal Sensitivity and Morphology during Antiangiogenic Treatment of Retinal Vein Occlusion over One Year

Ophthalmology

Volumn 116, Issue 12, 2009, Pages 2415-2421

  Kriechbaum, Katharina ^a   Prager, Franz ^a   Geitzenauer, Wolfgang ^a   Benesch, Thomas ^a   Schütze, Christopher ^a   Simader, Christian ^a   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MALE; MORPHOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA CYSTOID EDEMA; RETINA VEIN OCCLUSION; SCOTOMA; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PERIMETRY; PROSPECTIVE STUDIES; RETINA; RETINAL VEIN OCCLUSION; SCOTOMA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL FIELDS; VITREOUS BODY;

EID: 70649100328     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.05.001     Document Type: Article

References (27)

1. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
2. Costa R.A., Jorge R., Calucci D., et al. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27 (2007) 141-149
3. Gregori N.Z., Rosenfeld P.J., Puliafito C.A., et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 26 (2006) 889-895
4. Iturralde D., Spaide R.F., Meyerle C.B., et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26 (2006) 279-284
5. Drexler W., Sattmann H., Hermann B., et al. Enhanced visualization of macular pathology with the use of ultrahigh-resolution optical coherence tomography. Arch Ophthalmol 121 (2003) 695-706
6. Schmidt-Erfurth U., Leitgeb R.A., Michels S., et al. Three-dimensional ultrahigh-resolution optical coherence tomography of macular diseases. Invest Ophthalmol Vis Sci 46 (2005) 3393-3402
7. Srinivasan V.J., Wojtkowski M., Witkin A.J., et al. High-definition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 113 (2006) 2054-2065
8. Ko T.H., Fujimoto J.G., Duker J.S., et al. Comparison of ultrahigh- and standard-resolution optical coherence tomography for imaging macular hole pathology and repair. Ophthalmology 111 (2004) 2033-2043
9. Ko T.H., Fujimoto J.G., Schuman J.S., et al. Comparison of ultrahigh- and standard-resolution optical coherence tomography for imaging macular pathology. Ophthalmology 112 (2005) 1922-1935
10. Midena E., Radin P.P., Convento E., and Cavarzeran F. Macular automatic fundus perimetry threshold versus standard perimetry threshold. Eur J Ophthalmol 17 (2007) 63-68
11. Midena E., Vujosevic S., Convento E., et al. Microperimetry and fundus autofluorescence in patients with early age-related macular degeneration. Br J Ophthalmol 91 (2007) 1499-1503
12. Midena E., Degli Angeli C., Blarzino M.C., et al. Macular function impairment in eyes with early age-related macular degeneration. Invest Ophthalmol Vis Sci 38 (1997) 469-477
13. Kiss C.G., Barisani-Asenbauer T., Simader C., et al. Central visual field impairment during and following cystoid macular oedema. Br J Ophthalmol 92 (2008) 84-88
14. Rohrschneider K., Springer C., Bultmann S., and Volcker H.E. Microperimetry-comparison between the Micro Perimeter 1 and scanning laser ophthalmoscope-fundus perimetry. Am J Ophthalmol 139 (2005) 125-134
15. Springer C., Bultmann S., Volcker H.E., and Rohrschneider K. Fundus perimetry with the Micro Perimeter 1 in normal individuals: comparison with conventional threshold perimetry. Ophthalmology 112 (2005) 848-854
16. Kriechbaum K., Michels S., Prager F., et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92 (2008) 518-522
17. Jaissle G.B., Szurman P., and Bartz-Schmidt K.U. Recommendation for the implementation of intravitreal injections-statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). [in German]. Klin Monatsbl Augenheilkd 222 (2005) 390-395
18. Ahlers C., Simader C., Geitzenauer W., et al. Automatic segmentation in three-dimensional analysis of fibrovascular pigmentepithelial detachment using high-definition optical coherence tomography. Br J Ophthalmol 92 (2008) 197-203
19. Prager F., Michels S., Simader C., et al. Changes in retinal sensitivity in patients with neovascular age-related macular degeneration after systemic bevacizumab (Avastin) therapy. Retina 28 (2008) 682-688
20. Noma H., Funatsu H., Yamasaki M., et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 22 (2008) 42-48
21. Funk M., Kriechbaum K., Prager F., et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with nevacizumab. Invest Ophthalmol Vis Sci 50 (2009) 1025-1032
22. Prager F., Michels S., Kriechbaum K., et al. Intravitreal bevacizumab (Avastin) for macular edema secondary to retinal vein occlusion- twelve-month results of a prospective clinical trial. Br J Ophthalmol 93 (2009) 452-456
23. Luthra S., Narayanan R., Marques L.E., et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26 (2006) 512-518
24. Wu L., Martinez-Castellanos M.A., Quiroz-Mercado H., et al., Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246 (2008) 81-87
25. Rich R.M., Rosenfeld P.J., Puliafito C.A., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
26. Ahlers C., Golbaz I., Stock G., et al. Time course of morphologic effects on different retinal Compartments after ranibizumab therapy in age-related macular degeneration. [online report]. Ophthalmology 115 (2008) e39-e46. http://www.ophsource.org/periodicals/ophtha/article/S0161-6420(08)00455-7/abstract Accessed March 6, 2009
27. Davis M.D., Bressler S.B., Aiello L.P., et al., Diabetic Retinopathy Clinical Research Network Study Group. Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 49 (2008) 1745-1752